Your browser doesn't support javascript.
loading
Clinical Implications and Treatment Strategies for ESR1 Fusions in Hormone Receptor-Positive Metastatic Breast Cancer: A Case Series.
Brett, Jamie O; Ritterhouse, Lauren L; Newman, Erik T; Irwin, Kelly E; Dawson, Megan; Ryan, Lianne Y; Spring, Laura M; Rivera, Miguel N; Lennerz, Jochen K; Dias-Santagata, Dora; Ellisen, Leif W; Bardia, Aditya; Wander, Seth A.
Afiliación
  • Brett JO; Massachusetts General Hospital Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Ritterhouse LL; Massachusetts General Hospital Department of Pathology, Center for Integrated Diagnostics, Harvard Medical School, Boston, MA, USA.
  • Newman ET; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Irwin KE; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Dawson M; Massachusetts General Hospital Department of Orthopedic Surgery, Harvard Medical School, Boston, MA, USA.
  • Ryan LY; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Spring LM; Massachusetts General Hospital Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
  • Rivera MN; Massachusetts General Hospital Department of Psychiatry, Harvard Medical School, Boston, MA, USA.
  • Lennerz JK; University of Michigan Department of Psychiatry, University of Michigan Medical School, Ann Arbor, MI, USA.
  • Dias-Santagata D; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Ellisen LW; Massachusetts General Hospital Department of Medicine, Harvard Medical School, Boston, MA, USA.
  • Bardia A; Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.
  • Wander SA; Massachusetts General Hospital Department of Pathology, Center for Integrated Diagnostics, Harvard Medical School, Boston, MA, USA.
Oncologist ; 28(2): 172-179, 2023 02 08.
Article en En | MEDLINE | ID: mdl-36493359
In hormone receptor-positive metastatic breast cancer (HR+ MBC), endocrine resistance is commonly due to genetic alterations of ESR1, the gene encoding estrogen receptor alpha (ERα). While ESR1 point mutations (ESR1-MUT) cause acquired resistance to aromatase inhibition (AI) through constitutive activation, far less is known about the molecular functions and clinical consequences of ESR1 fusions (ESR1-FUS). This case series discusses 4 patients with HR+ MBC with ESR1-FUS in the context of the existing ESR1-FUS literature. We consider therapeutic strategies and raise the hypothesis that CDK4/6 inhibition (CDK4/6i) may be effective against ESR1-FUS with functional ligand-binding domain swaps. These cases highlight the importance of screening for ESR1-FUS in patients with HR+ MBC while continuing investigation of precision treatments for these genomic rearrangements.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Límite: Female / Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias de la Mama Límite: Female / Humans Idioma: En Revista: Oncologist Asunto de la revista: NEOPLASIAS Año: 2023 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Reino Unido